

Vimpat[®] (lacosamide) – First-time generic

- On April 8, 2022, [Indoco Remedies](#) and [Sagent Pharmaceuticals](#) launched [AP-rated](#) generic versions of UCB's [Vimpat \(lacosamide\)](#) injection.
- Vimpat is approved for the treatment of partial-onset seizures in patients 1 month of age and older, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Vimpat is also available as a brand oral solution and generic [tablet](#) that carry similar indications as the injection.
- According to IQVIA, Vimpat injection had annual sales of \$43.8 million.